

**BRIEF COMMUNICATION**

# Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients

Sebastian Heidt<sup>1</sup>  | Geert W. Haasnoot<sup>1</sup> | Marian D. Witvliet<sup>1</sup> | Marissa J. H. van der Linden-van Oevelen<sup>1</sup> | Elena G. Kamburova<sup>2</sup>  | Bram W. Wisse<sup>2</sup> | Irma Joosten<sup>3</sup> | Wil A. Allebes<sup>3</sup> | Arnold van der Meer<sup>3</sup> | Luuk B. Hilbrands<sup>4</sup> | Marije C. Baas<sup>4</sup> | Eric Spierings<sup>2</sup> | Cornelis E. Hack<sup>2</sup> | Franka E. van Reekum<sup>5</sup> | Arjan D. van Zuilen<sup>5</sup> | Marianne C. Verhaar<sup>5</sup> | Michiel L. Bots<sup>6</sup> | Adriaan C. A. D. Drop<sup>2</sup> | Loes Plaisier<sup>2</sup> | Marc A. J. Seelen<sup>7</sup> | Jan-Stephan Sanders<sup>7</sup> | Bouke G. Hepkema<sup>8</sup> | Annechien J. A. Lambeck<sup>8</sup> | Laura B. Bungener<sup>8</sup> | Caroline Roozendaal<sup>8</sup> | Marcel G. J. Tilanus<sup>9</sup> | Christina E. Voorter<sup>9</sup> | Lotte Wieten<sup>9</sup> | Elly M. van Duijnhoven<sup>10</sup> | Marielle A. C. J. Gelens<sup>10</sup> | Maarten H. L. Christiaans<sup>10</sup> | Frans J. van Ittersum<sup>11</sup> | Shaikh A. Nurmohamed<sup>11</sup> | Neubury M. Lardy<sup>12</sup> | Wendy Swelsen<sup>12</sup> | Karlijn A. M. I. van der Pant<sup>13</sup> | Neelke C. van der Weerd<sup>13</sup> | Ineke J. M. ten Berge<sup>13</sup> | Frederike J. Bemelman<sup>13</sup> | Andries Hoitsma<sup>14</sup> | Paul J. M. van der Boog<sup>15</sup> | Johan W. de Fijter<sup>15</sup> | Michiel G. H. Betjes<sup>16</sup>  | Henny G. Otten<sup>2</sup> | Dave L. Roelen<sup>17</sup> | Frans H. J. Claas<sup>1</sup>

<sup>1</sup>Eurotransplant Reference Laboratory, Leiden University Medical Center, Leiden, the Netherlands<sup>2</sup>Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands<sup>3</sup>Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Laboratory Medicine, Laboratory of Medical Immunology, Nijmegen, the Netherlands<sup>4</sup>Radboud University Medical Center, Department of Nephrology, Radboud Institute for Health Sciences, Nijmegen, the Netherlands<sup>5</sup>Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands<sup>6</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands<sup>7</sup>Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands<sup>8</sup>Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands<sup>9</sup>Department of Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Centre, Maastricht, the Netherlands<sup>10</sup>Department of Internal Medicine, Division of Nephrology, Maastricht University Medical Centre, Maastricht, the Netherlands<sup>11</sup>Department of Nephrology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands<sup>12</sup>Department of Immunogenetics, Sanquin Diagnostic Services, Amsterdam, the Netherlands<sup>13</sup>Department of Internal Medicine, Amsterdam University Medical Center, University of Amsterdam, Renal Transplant Unit, Amsterdam, the Netherlands

**Abbreviations:** HR, hazard ratio; AM, acceptable mismatch; CI, confidence interval; HB, heart beating; DGF, delayed graft function transplant through the Acceptable Mismatch program; DSA, donor-specific antibody; ETKAS, Eurotransplant kidney allocation system; IL2RA, IL-2 receptor antagonist; MMF, mycophenolate mofetil; NHB, non-heart beating.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2019 The Authors. *American Journal of Transplantation* published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.

<sup>14</sup>Dutch Organ Transplant Registry (NOTR), Dutch Transplant Foundation (NTS), Leiden, the Netherlands

<sup>15</sup>Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands

<sup>16</sup>Department of Nephrology, Erasmus Medical Center, Rotterdam, the Netherlands

<sup>17</sup>Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands

#### Correspondence

Sebastian Heidt

Email: s.heidt@lumc.nl

Whereas regular allocation avoids unacceptable mismatches on the donor organ, allocation to highly sensitized patients within the Eurotransplant Acceptable Mismatch (AM) program is based on the patient's HLA phenotype plus acceptable antigens. These are HLA antigens to which the patient never made antibodies, as determined by extensive laboratory testing. AM patients have superior long-term graft survival compared with highly sensitized patients in regular allocation. Here, we questioned whether the AM program also results in lower rejection rates. From the PROCARE cohort, consisting of all Dutch kidney transplants in 1995-2005, we selected deceased donor single transplants with a minimum of 1 HLA mismatch and determined the cumulative 6-month rejection incidence for patients in AM or regular allocation. Additionally, we determined the effect of minimal matching criteria of 1 HLA-B plus 1 HLA-DR, or 2 HLA-DR antigens on rejection incidence. AM patients showed significantly lower rejection rates than highly immunized patients in regular allocation, comparable to nonsensitized patients, independent of other risk factors for rejection. In contrast to highly sensitized patients in regular allocation, minimal matching criteria did not affect rejection rates in AM patients. Allocation based on acceptable antigens leads to relatively low-risk transplants for highly sensitized patients with rejection rates similar to those of nonimmunized individuals.

#### KEY WORDS

alloantibody, clinical research/practice, histocompatibility, immunogenetics, kidney transplantation/nephrology, major histocompatibility complex (MHC), rejection

## 1 | INTRODUCTION

Sensitization toward HLAs can occur through pregnancy, blood transfusion, or transplant.<sup>1</sup> When a patient has formed antibodies reactive >85% of HLA antigens present in the donor population, this patient is regarded as being highly sensitized.<sup>2</sup> Highly sensitized patients accrue on the transplant waitlist due to the low number of available cross-match-negative donors. The Eurotransplant Acceptable Mismatch program was established almost 30 years ago with the aim to provide a chance for highly sensitized patients to be transplanted, which has resulted in >1500 transplants.<sup>3</sup> The program is based on the positive identification of HLA antigens to which the patient has not made any antibodies by using extensive laboratory testing.<sup>4</sup> Acceptable antigens are added to the HLA phenotype of the patient, creating an "extended" HLA phenotype, which is used for allocation.<sup>5</sup> Any available deceased donor organ that matches this extended phenotype is mandatorily allotted to the AM patient, resulting in lower waiting times for these highly sensitized patients.<sup>6,7</sup> Acceptable antigens are truly acceptable, because no HLA match effect is observed in patients transplanted through the AM program.<sup>5,7</sup> Previously, it was shown that the long-term graft survival of patients transplanted through the

AM program is far superior to that of their highly sensitized counterparts transplanted through regular allocation and was even comparable to that of nonsensitized patients.<sup>7,8</sup> Because the AM strategy is targeted at defining HLA antigens that are immunologically acceptable, it is to be expected that allocation based on acceptable antigens would also result in a lower rejection incidence. Unfortunately, due to a lack of registration of rejection data in the Eurotransplant Network Information System, it has not been possible so far to determine the effect of the AM approach on rejection rates. The Dutch multicenter PROCARE study, which includes clinical follow-up of all kidney transplants performed between 1995 and 2005 in the Netherlands, allowed for the first time the determination of the effect of allocation on rejection rates based on acceptable mismatches.

## 2 | METHODS

### 2.1 | The AM program

Current eligibility criteria for inclusion into the AM program are a cumulative waiting time on the Eurotransplant Kidney Allocation System (ETKAS) waitlist of  $\geq 2$  years and a CDC PRA of >85% in either historic

**TABLE 1** Patient characteristics

| Parameters                                    | Categories               | ETKAS                |                      |                     | AM    | Total | P     |
|---|--------------------------|----------------------|----------------------|---------------------|-------|-------|-------|
|   |                          | 0-5% PRA<br>N = 1991 | 6-85% PRA<br>N = 968 | >85% PRA<br>N = 121 |       |       |       |
| Sex of recipient                              | Female                   | 34.3%                | 48.5%                | 59.5%               | 68.1% | 1301  | <.001 |
|   | Male                     | 65.7%                | 51.5%                | 40.5%               | 31.9% | 1892  |       |
| Sex of donor                                  | Female                   | 48.8%                | 44.6%                | 47.9%               | 43.4% | 1510  | .156  |
|   | Male                     | 51.2%                | 55.4%                | 52.1%               | 56.6% | 1683  |       |
| Age of recipient (y)                          | ≤50                      | 46.3%                | 53.9%                | 64.5%               | 64.6% | 1594  | <.001 |
|   | >50                      | 53.7%                | 46.1%                | 35.5%               | 35.4% | 1599  |       |
| Age of donor (y)                              | ≤50                      | 57.3%                | 63.1%                | 61.2%               | 58.4% | 1891  | .023  |
|   | >50                      | 42.7%                | 36.9%                | 38.8%               | 41.6% | 1302  |       |
| Donor type                                    | HB                       | 66.5%                | 73.9%                | 90.1%               | 99.1% | 2260  | <.001 |
|   | NHB                      | 33.5%                | 26.1%                | 9.9%                | 0.9%  | 933   |       |
| Repeat transplant                             | No                       | 93.4%                | 71.6%                | 40.5%               | 46.0% | 2654  | <.001 |
|   | Yes                      | 6.6%                 | 28.4%                | 59.5%               | 54.0% | 539   |       |
| HLA-A, -B, -DR mismatch (broad antigen level) | 1, 2, 3                  | 82.5%                | 81.7%                | 84.3%               | 90.3% | 2637  | .144  |
|   | 4, 5, 6                  | 17.5%                | 18.3%                | 15.7%               | 9.7%  | 556   |       |
| Transplant period                             | 1996-2000                | 45.0%                | 57.5%                | 63.6%               | 42.5% | 1577  | <.001 |
|   | 2001-2005                | 55.0%                | 42.5%                | 36.4%               | 57.5% | 1616  |       |
| Initial immunosuppression <sup>a</sup>        | Pred/cyclo ± MMF ± IL2RA | 65.8%                | 63.2%                | 64.7%               | 42.6% | 1497  | .002  |
|   | Pred/tacro/MMF ± IL2RA   | 34.2%                | 36.8%                | 35.3%               | 57.4% | 828   |       |
| Initial graft function <sup>b</sup>           | Direct                   | 64.5%                | 69.3%                | 67.3%               | 79.6% | 1991  | .002  |
|   | Delayed                  | 35.5%                | 30.7%                | 32.7%               | 20.4% | 997   |       |

AM, acceptable mismatch; cyclo, cyclosporine; HB, heart beating; IL2RA, interleukin-2 receptor antagonist; MMF, mycophenolate mofetil; NHB, non-heart beating; pred, prednisolone; tacro, tacrolimus.

<sup>a</sup>Missing values (n = 868), <sup>b</sup>missing values (n = 209). P-values calculated with  $\chi^2$  test.

or current serum samples. In the period of 1995-2005, acceptable antigens were defined by making use of mainly cellular assays, as described elsewhere.<sup>5</sup> Briefly, CDC assays were performed by using patient-specific cell panels of lymphocytes that had only 1 HLA mismatch with the patient, in which negative reactions would specify acceptable antigens. Similarly, a panel of K562 cell lines transfected with genes encoding single HLA class I alleles were used as targets in CDC. In the time period studied, solid phase assays were not routinely used.

For allocation purposes, HLA matching on the patient's own HLA antigens and additional acceptable antigens was performed on the split antigen level. Minimal match criteria on the identity of either 2 HLA-DR antigens or 1 HLA-DR antigen with 1 HLA-B antigen at the split level were adhered to. For patients with a chance of receiving a kidney through the AM program of <0.1% (based on immunological grounds), minimal HLA matching was reduced to 1 HLA-DR match with the patient on the broad antigen level. Furthermore, whereas regular allocation through ETKAS is based on blood group identity, AM patients are transplanted based on blood group compatibility.

## 2.2 | Patients

We performed a post hoc analysis on the PROCARE cohort, which includes all renal transplants performed in the Netherlands between January 1995 and December 2005 with available clinical follow-up.<sup>9</sup> All transplants required a negative CDC crossmatch using both peak and current sera. A detailed description of the cohort has been published previously.<sup>10</sup> Clinical data were obtained from the Dutch Organ Transplant Registry. Rejection was defined as the presence of biopsy-proved acute rejection (without further classification) or any treatment for acute rejection when no biopsy was performed. Patients transplanted through regular allocation (ETKAS) were grouped according to the level of sensitization (0% to 5% peak PRA: nonsensitized; 6% to 85% peak PRA: intermediately sensitized; and >85% peak PRA: highly sensitized), as defined by CDC assays. Patients included on the AM waitlist remained on the ETKAS waitlist as well, and those who were actually transplanted through ETKAS (and thus received an organ based on the absence of unacceptable antigens only) are included in the >85% PRA ETKAS

group. The study design is schematically depicted in Figure S1, and patient characteristics are depicted in Table 1. All patients provided written informed consent for use of their clinical data. The study protocol was approved by the Biobank Research Ethics Committee of the UMC Utrecht (TC Bio 13-633) and performed in accordance with the Declaration of Helsinki.

### 2.3 | Detection and definition of DSAs by solid phase

All available pretransplant patient sera were retrospectively tested for the presence of donor-specific antibodies (DSAs) by Luminex single antigen bead assays and analyzed in context of the PROCARE study as described previously.<sup>10</sup>

### 2.4 | Data handling

Groupings of quantitative variables were based on the following strategies: transplant period was divided into 2 equal periods, and recipient and donor ages of 50 years were used for stratification based on previous studies.<sup>11</sup> Donor type was defined as either heart beating (HB) or non-heart beating (NHB). Initial immunosuppression was categorized as prednisolone/cyclosporine with or without mycophenolate mofetil (MMF) with or without interleukin (IL)-2 receptor antagonist (IL2RA) versus prednisolone/tacrolimus/MMF with or without IL2RA based on a previous study on the complete PROCARE cohort.<sup>12</sup> Graft function was categorized on direct or delayed function, and HLA mismatches were divided into equal categories.


### 2.5 | Statistical analysis

The  $\chi^2$  test was used to test whether there was a trend in the proportions with transplant characteristics over the 4 categories. Statistical significance was determined by using the log-rank test, corrected for multiple comparisons (Bonferroni method), where applicable. Inclusion criterion for the multivariate analysis was a univariate *P*-value of  $<.1$ . Multivariate Cox regression analysis was performed to determine independent effects on 6-month cumulative rejection incidence. *P*-values were 2-tailed, and those  $<.05$  were considered statistically significant. SPSS version 23 (IBM, Armonk, NY) and GraphPad Prism, version 7.04 (GraphPad Software, La Jolla, CA) were used.

## 3 | RESULTS

### 3.1 | Allocation based on acceptable mismatches results in low rejection rates

To determine the effect of allocation based on acceptable mismatches on the 6-month cumulative rejection incidence, we selected all deceased donor single renal transplants from 1996 to 2005 (in 1996, ETKAS was initiated<sup>13</sup>) with  $\geq 1$  HLA antigen mismatch (HLA-A, -B, or -DR) at the broad antigen level. We observed an increased rejection incidence with increased sensitization grade within regular allocation, with the highest incidence of rejection in the highly sensitized patients transplanted through ETKAS (Figure 1A). In contrast, highly sensitized patients transplanted through the AM program showed




**FIGURE 1** A, Comparison of 6-month cumulative rejection incidence between patients transplanted through the acceptable mismatch (AM) program or through the Eurotransplant Kidney Allocation System (ETKAS). B, Comparison of 5-year cumulative rejection incidence between patients transplanted through the AM program or through ETKAS, for which rejection incidence was set at zero on 6 months. The ETKAS patients are subdivided based on their sensitization grade: 0% to 5% peak PRA: nonsensitized; 6% to 85% peak PRA: intermediately sensitized; and >85% peak PRA: highly sensitized. *P* value calculated with log-rank test and corrected for multiple comparisons (Bonferroni method)

**TABLE 2** Factors affecting 6-month cumulative rejection incidence of highly sensitized transplant recipients (>85% PRA) within PROCARE cohort (>0 HLA-A, -B, -DR mismatch)

|   | Cox regression |        |       |              |        |       |              |        |       |       |       |      |
|---|----------------|--------|-------|--------------|--------|-------|--------------|--------|-------|-------|-------|------|
|   | Univariate     |        |       | Multivariate |        |       | Multivariate |        |       |       |       |      |
|   | HR             | 95% CI | P     | HR           | 95% CI | P     | HR           | 95% CI | P     |       |       |      |
| Sex of recipient                              |                |        |       |              |        |       |              |        |       |       |       |      |
| Female (ref)                                  |                |        |       |              |        |       |              |        |       |       |       |      |
| Male  | 0.797          | 0.489  | 1.300 | .364         |        |       |              |        |       |       |       |      |
| Sex of donor                                  |                |        |       |              |        |       |              |        |       |       |       |      |
| Female (ref)                                  |                |        |       |              |        |       |              |        |       |       |       |      |
| Male  | 0.949          | 0.599  | 1.504 | .824         |        |       |              |        |       |       |       |      |
| Age of recipient (y)                          |                |        |       |              |        |       |              |        |       |       |       |      |
| ≤50 (ref)                                     |                |        |       |              |        |       |              |        |       |       |       |      |
| >50   | 0.819          | 0.502  | 1.334 | .422         |        |       |              |        |       |       |       |      |
| Age of donor (y)                              |                |        |       |              |        |       |              |        |       |       |       |      |
| ≤50 (ref)                                     |                |        |       |              |        |       |              |        |       |       |       |      |
| >50   | 1.240          | 0.781  | 1.969 | .362         |        |       |              |        |       |       |       |      |
| Donor type                                    |                |        |       |              |        |       |              |        |       |       |       |      |
| HB (ref)                                      |                |        |       |              |        |       |              |        |       |       |       |      |
| NHB   | 1.176          | 0.429  | 4.224 | .752         |        |       |              |        |       |       |       |      |
| Repeat transplant                             |                |        |       |              |        |       |              |        |       |       |       |      |
| No (ref)                                      |                |        |       |              |        |       |              |        |       |       |       |      |
| Yes   | 0.786          | 0.497  | 1.245 | .305         |        |       |              |        |       |       |       |      |
| HLA-A, -B, -DR mismatch (broad antigen level) |                |        |       |              |        |       |              |        |       |       |       |      |
| 1, 2, 3 (ref)                                 |                |        |       |              |        |       |              |        |       |       |       |      |
| 4, 5, 6                                       | 1.353          | 0.712  | 2.570 | .356         |        |       |              |        |       |       |       |      |
| Luminex defined DSA                           |                |        |       |              |        |       |              |        |       |       |       |      |
| No (ref)                                      |                |        |       |              |        |       |              |        |       |       |       |      |
| HLA class I                                   | 1.292          | 0.734  | 2.276 | .374         |        |       |              |        |       |       |       |      |
| HLA class II                                  | 0.691          | 0.240  | 1.991 | .493         |        |       |              |        |       |       |       |      |
| HLA class I and class II                      | 1.420          | 0.612  | 3.296 | .415         |        |       |              |        |       |       |       |      |
| Transplant period                             |                |        |       |              |        |       |              |        |       |       |       |      |
| 1996-2000 (ref)                               |                |        |       |              |        |       |              |        |       |       |       |      |
| 2001-2005                                     | 0.632          | 0.394  | 1.012 | .056         |        |       |              | 0.642  | 0.387 | 1.064 | .086  |      |
| Initial immunosuppression                     |                |        |       |              |        |       |              |        |       |       |       |      |
| Pred/cyclo ± MMF ± IL2RA (ref)                |                |        |       |              |        |       |              |        |       |       |       |      |
| Pred/tacro/MMF ± IL2RA                        | 0.581          | 0.306  | 1.104 | .097         | 0.665  | 0.345 | 1.282        | .223   |       |       |       |      |
| Initial graft function                        |                |        |       |              |        |       |              |        |       |       |       |      |
| Direct (ref)                                  |                |        |       |              |        |       |              |        |       |       |       |      |
| Delayed                                       | 1.941          | 1.190  | 3.167 | .008         |        |       |              | 1.925  | 1.163 | 3.187 | .011  |      |
| Tx through AM program                         |                |        |       |              |        |       |              |        |       |       |       |      |
| No (ref)                                      |                |        |       |              |        |       |              |        |       |       |       |      |
| Yes   | 0.469          | 0.290  | 0.758 | .002         | 0.541  | 0.272 | 1.073        | .079   | 0.569 | 0.342 | 0.945 | .029 |

AM, acceptable mismatch; CI, confidence interval; cyclo, cyclosporine; DSA, donor-specific antibody; HB, heart beating; HR, hazard ratio; IL2RA, interleukin-2 receptor antagonist; MMF, mycophenolate mofetil; NHB, non-heart beating; pred, prednisolone; ref, reference value; tacro, tacrolimus; Tx, transplant.



**FIGURE 2** Minimal match criteria do not affect rejection rates for patients transplanted through the Acceptable Mismatch (AM) program. A, The 6-month cumulative rejection incidence of highly sensitized patients transplanted through the Eurotransplant Kidney Allocation System (ETKAS) with a minimal match level of 1 HLA-B and 1 HLA-DR antigen, or 2 HLA-DR antigens on the split antigen level (equivalent to minimal match criteria), or transplanted with 1 HLA-DR match at the broad antigen level. B, The 6-month cumulative rejection incidence of AM patients transplanted according to the minimal match criteria of 1 HLA-B and 1 HLA-DR antigen, or 2 HLA-DR antigens on the split antigen level, or transplanted 1 HLA-DR match at the broad antigen level

similar rejection rates to those of nonsensitized patients ( $P = 1.000$ ) and lower, although not significant, rejection rates than intermediately sensitized patients ( $P = .423$ ). When compared with their highly sensitized counterparts transplanted through regular allocation, AM patients experienced a significantly lower rejection incidence ( $P = .004$ , Figure 1A). To determine the effect of the different allocation schemes on rejection rates later after transplant, we also analyzed the cumulative rejection incidence between 6 months and 5 years and observed no differences in this later period (Figure 1B).

We next performed univariate Cox regression analysis on all highly sensitized patients ( $n = 234$ ) with variables that potentially affect the rejection incidence (Table 2). The variables of sex and age of the recipient and the donor, donor type, first transplant versus repeat transplant, HLA mismatch grade, transplant period, initial immunosuppression, and presence of single antigen bead-detected DSAs of class I, class II, or both class I and class II did not significantly affect the cumulative 6-month rejection incidence. The only variables that affected the incidence of rejection were delayed graft function (hazard ratio [HR] 1.94, 95% confidence interval [CI] 1.19 to 3.17;  $P = .008$ ) and receiving a transplant through the AM program (HR 0.47, 95% CI 0.29 to 0.76;  $P = .002$ ). The variables of transplant period, initial immunosuppression, initial graft function, and transplant through the AM program were selected for subsequent multivariate analysis to determine whether the effect of receiving a transplant through the AM program was independent. For initial immunosuppression, there were missing values for 88 patients (38%) due to heterogeneous immunosuppression protocols outside the 2

main immunosuppression categories. To exclude an interaction between initial immunosuppression and transplant through the AM program, we first analyzed these variables in a separate multivariate analysis and observed only a minimal effect of initial immunosuppression on the variable transplant through the AM program (HR changes from 0.47 to 0.54, Table 2). Subsequent multivariate analyses on transplant period, initial immunosuppression, initial graft function, and transplant through the AM program showed that only delayed graft function (HR 1.93, 95% CI 1.16 to 3.19;  $P = .011$ ) and receiving a transplant through the AM program (HR 0.57, 95% CI 0.34 to 0.95;  $P = .029$ ) were independently associated with 6-month cumulative rejection incidence (Table 2).

### 3.2 | Minimal match criteria do not result in lower rejection rates in AM patients

It has previously been shown that AM patients transplanted with a minimal match level of 2 HLA-DR antigens or of 1 HLA-DR and 1 HLA-B antigen have similar graft survival rates compared with AM patients without this minimal level of HLA matching, raising the possibility that the minimal match criteria for AM patients could be abandoned.<sup>3</sup> Importantly, in the current cohort we were able to determine the effect of the minimal match criteria on rejection rates. For this analysis, we also included patients with 0 HLA mismatches (Figure S1). We found that receiving a transplant without the aforementioned minimal match level, but a minimum match of 1 HLA-DR on the broad antigen level, significantly increased the 6-month

cumulative rejection incidence in patients transplanted through ETKAS ( $P < .0001$ , Figure 2A), whereas no effect was found in the AM cohort ( $P = .700$ , Figure 2B). The data indicate that the minimal match criteria are not beneficial over 1 HLA-DR broad antigen match for patients transplanted through the AM program.

## 4 | DISCUSSION

It is known that transplant to sensitized patients through regular allocation is associated with an elevated risk for graft rejection.<sup>14-16</sup> The current study confirms these data, with the cumulative rejection incidence for highly sensitized patients transplanted through ETKAS being almost double that of nonsensitized ETKAS patients. In contrast, patients transplanted through the AM program showed significantly lower rejection rates compared with highly sensitized patients transplanted through regular allocation and even had similar rejection rates as nonsensitized patients. On multivariate analysis, receiving a transplant through the AM program remained independently associated with low rejection rates in highly sensitized patients. The occurrence of rejection is known to be a risk factor for subsequent inferior long-term graft survival.<sup>17</sup> Indeed, it has been described previously that graft survival in AM patients is far superior to that in highly sensitized patients transplanted through ETKAS and comparable to that in nonsensitized ETKAS patients.<sup>7</sup> Limitations of the study are that it does not include information on whether the rejections were biopsy proven. In the PROCARE database, rejection was defined as a registered treatment for rejection, of which 56.4% ( $n = 456$ ) were accompanied by a documented biopsy specimen taken a day before or at the day of initiation of antirejection treatment, a percentage that was evenly distributed between the different groups ( $P = .122$ , Table S1). This is likely an underestimation due to incompleteness of the database for this field. To obtain a more stringent selection on the rejection events, we determine the 6-month cumulative rejection of highly sensitized patients (ETKAS and AM) without any rejection or who received a documented biopsy-informed antirejection treatment defined as described earlier and again found that patients transplanted through AM had a significantly lower rejection incidence than their highly sensitized counterparts transplanted through (Figure S2).

Second, we were unable to further differentiate in type of rejection, because a classification of rejection is not available from the Dutch Organ Transplant Registry and cannot be obtained retrospectively due to the various changes in BANFF criteria over time. Finally, there are no data available regarding development of de novo DSAs in the current cohort. With the current study showing a marked benefit for AM patients, these parameters should be included in a consecutive study on a more recent cohort.

The finding that allocation based on acceptable antigens results in low rejection rates and excellent long-term graft survival can be explained in several ways. First, the absence of particular HLA antibody specificities is actively determined for AM patients in both historic and current sera, in contrast to regular allocation in which unacceptable antigens are determined and all other antigens are presumed acceptable.

Second, there is evidence that acquired neonatal tolerance explains a proportion of acceptable antigens, because acceptable antigens often include the noninherited maternal antigens.<sup>18,19</sup> Third, either acceptable antigens could harbor a low level of epitope mismatches with the patient or the epitope mismatches that are present are of low immunogenicity.<sup>20</sup> Preliminary data suggest the latter, because analysis for HLA class I shows similar levels of epitope mismatches for AM patients and patients transplanted through regular allocation, with no effect of the number of epitope mismatches on graft survival for AM patients (Heidt et al, manuscript in preparation).

Currently, acceptable antigens for HLA-DQA, HLA-DPA, and HLA-DPB are not yet accounted for in the AM program, which leaves the possibility that rejection rates for AM patients could be even lower when these loci are also taken into consideration. Indeed, HLA-DQ seems to be the dominant target for HLA antibodies after transplant.<sup>21,22</sup> Future analyses should show whether extension of acceptable mismatches to these additional loci will indeed lead to better outcome. Such analyses should preferentially be performed in the whole AM population, because in the current study only transplants performed in the Netherlands were included. However, the definition of acceptable antigens is done centrally at the Eurotransplant Reference Laboratory, using the same criteria for all patients within Eurotransplant. While confirmation of our results within the whole of Eurotransplant is desirable, we expect similar results to the current study.

In addition to a previously described lack of effect of minimal match criteria on long-term graft survival in AM patients,<sup>3</sup> we show a lack of effect on rejection incidence as well, confirming that acceptable mismatches are truly acceptable. Together, these data strongly support downscaling the minimal match criteria for AM patients to 1 HLA-DR broad antigen match, which can result in around 200 additional transplants to highly sensitized patients through the AM program each year.<sup>3</sup>

Timely transplant of highly sensitized patients is of the utmost importance but should be accompanied by low rejection rates and long-term graft survival to have a true impact on the waitlist of highly sensitized patients. We show that transplant of highly sensitized patients can be achieved with comparable rejection rates to nonsensitized patients, when acceptable mismatches are used in the allocation process.

## AUTHOR CONTRIBUTIONS

Drs Heidt, Haasnoot, van der Linden-van Oevelen, MW, and FC analyzed the data. Drs Kamburova, TK, Wisse, Joosten, Allebes, AvdM, Hilbrands, Baas, Spierings, Hack, van Reekum, van Zuilen, Verhaar, Bots, Drop, PlaisierJeelen, NB, MS, Sanders, Hepkema, Lambeck, Bungener, Roozendaal, Tilanus, JV, Voorter, Wieten, van Duijnhoven, Gelen, Christiaans, van Ittersum, Nurmohamed, Lardy, Swelsen, van der Pant, van der Weerd, ten Berge, Bemelman, Hoitsma, van der Boog, de Fijter, MB, Heidt, DR, FC, and HO contributed reagents/materials/analysis tools. Drs Hilbrands, MCB, van Reekum, van Zuilen, Verhaar, Seelen, Sanders, van Duijnhoven, Gelen, Christiaans,

van Ittersum, Nurmohamed, van der Pant, van der Weerd, ten Berge, Bemelman, Hoitsma, van der Boog, de Fijter, and Baas evaluated kidney transplant patients. Drs Heidt, GH, van der Linden, van Oevelen, Witvliet, FC, HO, FB, Baas, BH, ten Berge, CV, and Hilbrands contributed to writing of the manuscript. All authors reviewed and approved the final version of the manuscript.

## ACKNOWLEDGMENTS

The PROCARE study was supported by research funding from Dutch Kidney Foundation project code CP12.23 (risk assessment of kidney graft failure by HLA antibody profiling). The authors thank the Eurotransplant staff and all Eurotransplant HLA laboratories and transplantation centers for their constructive collaboration and participation in the AM program.

## DISCLOSURE

The authors of this manuscript have no conflicts of interest to disclose as described by the *American Journal of Transplantation*.

## DATA AVAILABILITY STATEMENT

Data available on request due to privacy/ethical restrictions.

## ORCID

Sebastiaan Heidt  <https://orcid.org/0000-0002-6700-188X>

Elena G. Kamburova  <https://orcid.org/0000-0002-6927-2683>

Michiel G. H. Betjes  <https://orcid.org/0000-0001-9435-6208>

## REFERENCES

- Scornik JC, Brunson ME, Howard RJ, Pfaff WW. Alloimmunization, memory, and the interpretation of crossmatch results for renal transplantation. *Transplantation*. 1992;54(3):389-394.
- Heidt S, Claas FHJ. Transplantation in highly sensitized patients: challenges and recommendations. *Expert Rev Clin Immunol*. 2018;14(8):673-679.
- Heidt S, Haasnoot GW, Claas FHJ. How the definition of acceptable antigens and epitope analysis can facilitate transplantation of highly sensitized patients with excellent long-term graft survival. *Curr Opin Organ Transplant*. 2018;23(4):493-499.
- Claas FH, Doxiadis II. Management of the highly sensitized patient. *Curr Opin Immunol*. 2009;21(5):569-572.
- Heidt S, Witvliet MD, Haasnoot GW, Claas FH. The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients. *Transpl Immunol*. 2015;33(2):51-57.
- Claas FHJ, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis IIN. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. *Transplantation*. 2004;78(2):190-193.
- Heidt S, Haasnoot GW, van Rood JJ, Witvliet MD, Claas FHJ. Kidney allocation based on proven acceptable antigens results

in superior graft survival in highly sensitized patients. *Kidney Int*. 2018;93(2):491-500.

- Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. *Transplantation*. 2009;88(4):447-452.
- Otten HG, Joosten I, Alledes WA, et al. The PROCARE consortium: toward an improved allocation strategy for kidney allografts. *Transpl Immunol*. 2014;31(4):184-190.
- Kamburova EG, Wisse BW, Joosten I, et al. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. *Am J Transplant*. 2018;18(9):2274-2284.
- Doxiadis II, de Fijter JW, Mallat MJ, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. *Transplantation*. 2007;83(9):1207-1213.
- Michielsen L, van Zuilen A, Wisse B, et al. Effect of initial immunosuppression on long term kidney transplant outcome in immunological low risk patients. *Nephrol Dial Transplant*. 2018;33:39.
- Doxiadis IIN, Smits JMA, Persijn GG, Frei U, Claas FHJ. It takes six to boogie: allocating cadaver kidneys in Eurotransplant. *Transplantation*. 2004;77(4):615-617.
- Song EY, Lee YJ, Hyun J, et al. Clinical relevance of pretransplant HLA class II donor-specific antibodies in renal transplantation patients with negative T-cell cytotoxicity crossmatches. *Ann Lab Med*. 2012;32(2):139-144.
- Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. *Am J Transplant*. 2008;8(2):324-331.
- Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. *Transplantation*. 2009;87(11):1681-1688.
- Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. *Lancet*. 2013;381(9863):313-319.
- Claas FH, Gijbels Y, van der Velden-de Munck J, van Rood JJ. Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. *Science*. 1988;241(4874):1815-1817.
- Burlingham WJ, Grailler AP, Heisey DM, et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. *N Engl J Med*. 1998;339(23):1657-1664.
- Kramer CSM, Roelen DL, Heidt S, Claas FHJ. Defining the immunogenicity and antigenicity of HLA epitopes is crucial for optimal epitope matching in clinical renal transplantation. *HLA*. 2017;90(1):5-16.
- Campos EF, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. *Am J Transplant*. 2006;6(10):2316-2320.
- Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. *Transplantation*. 2012;94(2):172-177.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Heidt S, Haasnoot GW, Witvliet MD, et al. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. *Am J Transplant*. 2019;19:2926-2933. <https://doi.org/10.1111/ajt.15486>